| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6677326 | HORIZON | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration |
Mar, 2020
(4 years ago) | |
| US6488960 | HORIZON | Corticosteroid formulation |
Mar, 2020
(4 years ago) | |
| US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(4 days ago) | |
| US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(4 days ago) | |
| US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(4 days ago) | |
| US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(4 days ago) | |
| US9504699 | HORIZON | Delayed-release glucocorticoid treatment of rheumatoid disease |
Aug, 2027
(3 years from now) | |
| US8168218 | HORIZON | Delayed release tablet with defined core geometry |
Jan, 2028
(3 years from now) | |
Rayos is owned by Horizon.
Rayos contains Prednisone.
Rayos has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Rayos are:
- US6677326
- US6488960
- US9040085
- US9186332
- US8309124
- US8394407
Rayos was authorised for market use on 26 July, 2012.
Rayos is available in tablet, delayed release;oral dosage forms.
Rayos can be used as treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone, treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet, treatment of rheumatoid arthritis by delayed release formulation of 1mg or 2mg of prednisone, treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet.
The generics of Rayos are possible to be released after 07 January, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Jul 26, 2015 |
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone; Treatment of rheumatoid arthritis by delayed rel...
Dosage: TABLET, DELAYED RELEASE;ORAL
RAYOS family patents
